Metabolism changes and reproductive function state during Dibicor use in women with polycystic ovary syndrome


Cite item

Full Text

Abstract

The article discusses the first experience of use of the native drug Dibicorum (Taurine) for the correction of metabolic and reproductive disorders in women with infertility secondary to polycystic ovarian syndrome (PCOS). It is known that the use of insulin-sensitizing agents, indirectly, on the background of improvement of sensitivity to the hormone, in some cases can lead to reduction of available reproductive disorders and improvement of fertility. However, not all patients tolerate this therapy (eg, women with low body weight). In addition, these drugs have contraindications for use. These factors formed the basis for assessment of taurine effects in this cohort of patients. The authors surveyed 51 women with diagnosed PCOS before and after treatment with Dibicorum at dose of 1000 mg for 12 weeks. The reliable findings showed that Dibicorum modulates metabolic disorders in patients with PCOS by decrease of β-cell dysfunction. It leads to decrease of degree of hyperinsulinemia and activation of selection of leading follicles in patients with anovulatory ovarian dysfunction.

References

  1. Манухин И.Б., Геворкян М.А. Синдром поликистозных яичников // Проблемы репродукции.1999. 6. С. 13-18.
  2. Манухин И.Б., Геворкян М.А., Минкина Г.Н., Студеная Л.Б. Метаболические нарушения у женщин с синдромом поликистозных яичников // Проблемы репродукции. 1999. 4. С. 7-13.
  3. Taylor AE. Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implication. Am J Obstet Gynecol 1998;l(170):94-100.
  4. Barnes RB, Daniels G. Insulin resistance in polycystic ovary syndrome. N Engl J Med 1987;322:489-99.
  5. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-116.
  6. Dunaif A, Segal KR, Green G, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1993;41:1257-66.
  7. Eil S, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 1984;59:51-56.
  8. Elkind-Hirsch KE, Valdes CT, Malinak LR. Insulin resistance in hyperandrogenic women treated with lupron. Fertil Steril 1993;60(4):634-64.
  9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin Chemistry 1972;18:499-502.
  10. Gharani N, Waterworth DM, Batty S. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-405.
  11. Grassinger CC, Wild RA, Parker IJ. Vulvar acantosis nigricans: a marker for insulin resistance in hirsute women. Fertil Steril 1993;59(33):583-86.
  12. Khan CR, Flier JS, Bar RS, et al. The synehomes of insulin resistance and acanthosis nigricans: Insulin receptor disorders in man. New Engl J Med 1976;294:739-745.
  13. Manson JE, Faich GA. Insulin and the polycystic ovary syndrome. N Engl J Med 1996;335(9):657-60.
  14. Овсянникова Т.В. Синдром поликистозных яичников, как причина нарушения репродуктивной функции //РМЖ.2000. 8(18).C. 755-59.
  15. Пищулин А.А., Бутов А.В., Удовиченко О.В. Синдром овариальной ГА неопухолевого генеза (обзор литературы) // Пробл. репродукции. - 1999. - №3. - с. 6-16(статья в журнале).
  16. Chiu K. C., Lee N. P., Cohan P., Chaung L. Beta cell function declines with age in glucose yolerant Caucasians // Clin Endocrinol. - 2000. - 53. - P. 569-575(иностранный источник).
  17. Conway G.S., Avey C., Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome // Hum. Reprod. - 1994. - 9. - P. 1681-1683(иностранный источник).
  18. Kahn S. E., Prigeon R. L., McCullochD. K. Quantification of the relation between insulin sensitivity and β-cell function in human subjects // Diabetes. - 1993. - 42. - P. 1663-1672(иностранный источник).
  19. O'Meara N. M., Blackman J. D., Ehrmann D. A. et al Defects in beta-cell function in functional ovarian hyperandrogenism // J. Clin. Endocrinol. Metab. - 1993. - 76. - P. 1241-1247.
  20. Schonal J., Hyperinsulinaemia in pathogenesis of polycystic ovaries // Metab. - 1993. - 44. - P. 451-496(иностранный источник).
  21. van Haeften T. W, Pienta W., Mitrakou M., Korytkowski M., Jenssen T. Relatibve contribution of β-cell function and tissue insulin sensitivity to fasting and postglucose load glycemia. // Metabolism. - 2000. - vol. 49. - P. 1318-1325(иностранный источник).
  22. Conn J. J., Jacobs H. S., Conway G. S. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus // Clin Endocrinol. - 2000. - 52. - P. 81-86(иностранный источник).
  23. Legro R. S., Dodson W. C., Dunaif A. PCOS: a reservoir of reproductive age glucose intolerance poorly detected by fasting blood glucose levels (abstract OR41-3). // Proceedings of the Endocrine Society 80th annual Meeting, New Orleans, La., Lune 24-28, 1998(иностранный источник).
  24. Mitrakou A., Vuirinen-Markkola H., Raptis G. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp // J. Clin. Endocrinol. Metab. - 1992. - P. 75. - 379-982(иностранный источник).
  25. van Haeften T. W., Stumvol M. --to: Albareda M et al. Assessement of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test // Diabetologia. - 43. - 2001. - 44. - P. 1507-1511(иностранный источник).
  26. Fair G. W., Swan K. X. Theraputical options in polycystic ovary syndrome // Endoc Metab. - 1993. - 28. - P. 331-340(иностранный источник).
  27. Jakubowicz D. J., Nestler J. E. 17--Hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss // J. Clin. Endocrinol. Metab. - 1997. - 82. - P. 556-560 (иностранный источник).
  28. Legro R.S. Polycystic ovary syndrome: current and future treatment paradigms // Am J. Obstet. Gynecol. - 1998. - vol. 179. - №6. - P. S101-S108(иностранный источник).
  29. Nestler J. E., Jakubowicz D. J., Reamer P. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome // N Engl J Med. - 1999. - 340. - P. 1314-1320(иностранный источник).
  30. Oversen P. G., Moller A., Greisen S., Ingerslev H.J. Polycyslic ovary syndrome I. Clinical presentation and treatment // Ugeskr Laeger. - 1998. - vol. 160. - №3. - P. 260-264 (иностранный источник).
  31. Gokmen O., Senoz S., Gulekli B. et al Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome // Gynecol Endocrinol. - 1996. - vol. 10. -№4. - P. 249-254(иностранный источник).
  32. Hatch R., Rosenfield R.S., Kim M.H., Tredway D. Hirsutism: Implications, etiology, and management // Am. J. Obstet. Gynecol. - 1981. - 140. - P. 815-820 (иностранный источник).
  33. Kuttenn F., Rigaud C., Wright F., Mauvuis-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol // J. Clin. Endocrinol. Metab. -1980. - 51. - P. 1107-1111 (иностранный источник).
  34. Sonino N et al: Quality of life of hirsute women // Postgrad Med J. - 1993. - 69. - P. 186-192 (иностранный источник).
  35. Berga S. L. The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome // Am. J. Obstet. Gynecol. - 1999. - vol. 179. -№6. - S109-S113 (иностранный источник).
  36. Bergman R. N. 1989 Lilly lecture. Towards physiological understanding of glucose intolerance. Minimal midel approach // Diabetes. - 1989. - 38. - P. 1512-1527 (иностранный источник).
  37. Andersen P. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome //Metabolism. -1995. - 44. - P. 611-617(иностранный источник) .
  38. Chang R. J., Nakamura R. M., Judd H. L., Kaplan S. A. Insulin resistance in nonobese patients with polycystic ovarian disease // J. Clin. Endocrinol. Metab. - 1983. - 57. - P. 356-359(иностранный источник) .
  39. Guzick D. S., Wing R., Smith D., Berga S. L., Winters S. L. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatorv women // Fertil. Steril. - 1994. - 61. - P. 598-604(иностранный источник).
  40. Huber-Buchholz M. M., Carey D. G., Norman R. J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone // J. Clin. Endocrinol. Metab. - 1999. - 84. - P. 1470- 1476 (иностранный источник).
  41. Kalinen T.A., Antilla L., Erkkola. R., Koskinen. P., Laippola. P. et al. Hormonal responses to physical exercise in patients with polycystic ovary syndrome // Fertil. Steril. - 1993. - 60. - P. 262-267 (иностранный источник).
  42. Legro R.S. Polycystic ovary syndrome: current and future treatment paradigms // Am J. Obstet. Gynecol. - 1998. - vol. 179. - №6. - P. S101-S108 (иностранный источник).
  43. Carlsen S. M., Rossvoll O., Bjerve K. S. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease // J Intern Med. - 1997. - vol. 242. -№5. - P. 407-412(иностранный источник).
  44. De Leo V., La Marca A., Ditto A., Morgante G., Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome // Fertil. Steril. - 1999. - vol. 72. - №2. - P. 282-285(иностранный источник).
  45. DeFronzo R. A., Barzilai N. Simonson D. C. Mechanism of metformin action in obese and lean non-insulin dependent diabetic subjects // J. Clin. Endocrinol. Metab. - 1991. - 73. - P. 1294 - 1301 (иностранный источник).
  46. Dorella M., Giusto M., Da Tos V., Campagnolo M. et al Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance // J Clin Endocrinol Metab. - 1995. - 81. - P. 1568-74.
  47. Glueck C. J., Wang P., Fontaine R., Tracy T., Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome // Metabolism. - 1999. - vol. 48. - №4. - P. 511-519.
  48. Kidson W. Polycystic ovary syndrome: a new direction in treatment // Med. J. Aust. - 1998. - vol. 169. - №10. - P. 537-540 (иностранный источник).
  49. Snorgaard O., Kober L., Carlsen H. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients // J. Intern. Med. - 1997. - vol. 242. - №5. - P. 407-412(иностранный источник).
  50. Зыкова Т.А., Стрелкова А.В. Метаболические аспекты регуляции менструального цикла у здоровых женщин и у женщин с различными клиническими фенотипами СПКЯ. Статья в журнале «Эфферентная терапия», т.13, п.1, 2007, с.28-30 (статья в журнале).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies